{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:57:54Z","timestamp":1790495874042,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.autrev.2026.104089","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:54:11Z","timestamp":1779231251000},"page":"104089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The rituximab paradox in rheumatoid arthritis: Re-evaluating B-cell depletion depth and the synovial microenvironment"],"prefix":"10.1016","volume":"25","author":[{"given":"Cheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.autrev.2026.104089_bb0005","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.autrev.2026.104089_bb0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1016\/j.autrev.2026.104089_bb0015","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104089_bb0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2007.02.017","article-title":"B cells in rheumatoid arthritis","volume":"7","author":"Bugatti","year":"2007","journal-title":"Autoimmun Rev"},{"issue":"Suppl. 4","key":"10.1016\/j.autrev.2026.104089_bb0025","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1010","article-title":"Roles of B cells in rheumatoid arthritis","volume":"5","author":"Silverman","year":"2003","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2026.104089_bb0030","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00002281-200305000-00011","article-title":"The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets","volume":"15","author":"D\u00f6rner","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104089_bb0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","author":"Klein","year":"2013","journal-title":"MAbs"},{"issue":"22","key":"10.1016\/j.autrev.2026.104089_bb0040","first-page":"4393","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell\u2013mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood,TJ Am Soc Hematol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104089_bb0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","article-title":"New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies","volume":"25","author":"Robak","year":"2011","journal-title":"BioDrugs"},{"issue":"8","key":"10.1016\/j.autrev.2026.104089_bb0050","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/art.39167","article-title":"Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus","volume":"67","author":"Reddy","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104089_bb0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104089_bb0060","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2026.104089_bb0065","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.23732","article-title":"Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104089_bb0070","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/art.33317","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight\u2013week randomized, double-blind, placebo-controlled, parallel-group phase III trial","volume":"64","author":"Rigby","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2026.104089_bb0075","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1136\/ard.2011.151522","article-title":"Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial","volume":"70","author":"Taylor","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104089_bb0080","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3899\/jrheum.121118","article-title":"Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I\/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics","volume":"40","author":"Kurrasch","year":"2013","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104089_bb0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","article-title":"Rituximab for rheumatoid arthritis","volume":"2","author":"Cohen","year":"2015","journal-title":"Rheumatol Ther"},{"issue":"3","key":"10.1016\/j.autrev.2026.104089_bb0090","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/rheumatology\/kex446","article-title":"Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection","volume":"57","author":"Henry","year":"2018","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.autrev.2026.104089_bb0095","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10041","key":"10.1016\/j.autrev.2026.104089_bb0100","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(16)00380-9","article-title":"Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial","volume":"388","author":"Porter","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104089_bb0105","first-page":"87","article-title":"Rituximab for the treatment of rheumatoid arthritis: an update","author":"Mok","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"21","key":"10.1016\/j.autrev.2026.104089_bb0110","article-title":"Reframing immune-mediated inflammatory diseases","volume":"385","author":"Boutrid","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104089_bb0115","first-page":"2146","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheumat Off J Am College Rheumatol"},{"issue":"7811","key":"10.1016\/j.autrev.2026.104089_bb0120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-020-2222-z","article-title":"Notch signalling drives synovial fibroblast identity and arthritis pathology","volume":"582","author":"Wei","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.autrev.2026.104089_bb0125","first-page":"1305","article-title":"Toll-like receptor 7 (TLR7)\u2013driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity","volume":"118","author":"Rubtsov","year":"2011","journal-title":"Blood,TJ Am Soc Hematol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104089_bb0130","article-title":"B cells in autoimmune diseases","volume":"2012","author":"Hampe","year":"2012","journal-title":"Scientifica"},{"issue":"7","key":"10.1016\/j.autrev.2026.104089_bb0135","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104089_bb0140","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/s41467-018-03750-7","article-title":"IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.autrev.2026.104089_bb0145","first-page":"6300633","article-title":"Analyzation of the peripheral blood mononuclear cells atlas and cell communication of rheumatoid arthritis patients based on single-cell RNA-Seq","volume":"2023","author":"Song","year":"2023","journal-title":"J Immunol Res"},{"issue":"11","key":"10.1016\/j.autrev.2026.104089_bb0150","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/ard-2022-222605","article-title":"Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-\u03b1-mediated ERK1\/2 and JAK-STAT1 pathways","volume":"81","author":"Qin","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7760","key":"10.1016\/j.autrev.2026.104089_bb0155","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.autrev.2026.104089_bb0160","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/ard-2024-225778","article-title":"ITGA5+ synovial fibroblasts orchestrate proinflammatory niche formation by remodelling the local immune microenvironment in rheumatoid arthritis","volume":"84","author":"Zheng","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"7639","key":"10.1016\/j.autrev.2026.104089_bb0165","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.autrev.2026.104089_bb0170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130062","article-title":"PD-1hiCXCR5\u2013T peripheral helper cells promote B cell responses in lupus via MAF and IL-21","volume":"4","author":"Bocharnikov","year":"2019","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.autrev.2026.104089_bb0175","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","article-title":"Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes","volume":"16","author":"Nygaard","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104089_bb0180","doi-asserted-by":"crossref","first-page":"1394108","DOI":"10.3389\/fimmu.2024.1394108","article-title":"Macrophage polarization in rheumatoid arthritis: signaling pathways, metabolic reprogramming, and crosstalk with synovial fibroblasts","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104089_bb0185","first-page":"119","article-title":"Tertiary lymphoid organs in rheumatoid arthritis","volume":"426","author":"Rivellese","year":"2020","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104089_bb0190","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104089_bb0195","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0394632015593228","article-title":"TNF-a mediated inflammatory macrophage polarization contributes to the pathogenesis of steroid-induced osteonecrosis in mice","volume":"28","author":"Wu","year":"2015","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104089_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22925","article-title":"Predicting anti-TNF treatment response in rheumatoid arthritis: an artificial intelligence-driven model using cytokine profile and routine clinical practice parameters","volume":"10","author":"Valdivieso Shephard","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.autrev.2026.104089_bb0205","series-title":"National Institute for Health and Care Research Copyright \u00a9 Queen\u2019s Printer and Controller of HMSO","article-title":"Efficacy and mechanism evaluation, rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT","author":"Humby","year":"2022"},{"key":"10.1016\/j.autrev.2026.104089_bb0210","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3389\/fimmu.2020.00845","article-title":"A Pauci-immune synovial Pathotype predicts inadequate response to TNF\u03b1-blockade in rheumatoid arthritis patients","volume":"11","author":"Nerviani","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104089_bb0215","series-title":"Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: The R4-RA RCT","author":"Humby","year":"2022"},{"issue":"11","key":"10.1016\/j.autrev.2026.104089_bb0220","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","article-title":"Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials","volume":"5","author":"Rivellese","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104089_bb0225","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1042\/bst0300824","article-title":"B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders","volume":"30","author":"Edwards","year":"2002","journal-title":"Biochem Soc Trans"},{"issue":"25","key":"10.1016\/j.autrev.2026.104089_bb0230","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.autrev.2026.104089_bb0235","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"issue":"22","key":"10.1016\/j.autrev.2026.104089_bb0240","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.autrev.2026.104089_bb0245","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104089_bb0250","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/DDDT.S104869","article-title":"Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy","volume":"11","author":"Al-Sawaf","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"10.1016\/j.autrev.2026.104089_bb0255","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.23732","article-title":"Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104089_bb0260","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11033-025-10366-w","article-title":"Rheumatoid arthritis unmasked: the power of B cell depletion therapy","volume":"52","author":"Alghazali","year":"2025","journal-title":"Mol Biol Rep"},{"issue":"3","key":"10.1016\/j.autrev.2026.104089_bb0265","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104089_bb0270","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104089_bb0275","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B cells are Major targets for effective immunotherapy in relapsing multiple sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.autrev.2026.104089_bb0280","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1513\/AnnalsATS.201512-848OC","article-title":"The impact of age and comorbidities on the mortality of patients of different age groups admitted with community-acquired pneumonia","volume":"13","author":"Luna","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.autrev.2026.104089_bb0285","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104089_bb0290","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104089_bb0295","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/S2665-9913(19)30066-9","article-title":"Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial","volume":"1","author":"Verhoef","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104089_bb0300","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003659","article-title":"Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial","volume":"10","author":"den Broeder","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.autrev.2026.104089_bb0305","doi-asserted-by":"crossref","first-page":"rkaa077","DOI":"10.1093\/rap\/rkaa077","article-title":"Low-dose rituximab protocol in rheumatoid arthritis-outcome and economic impact","volume":"5","author":"Chandramohan","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.autrev.2026.104089_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpg.2025.101992","article-title":"Biobetters and biosimilars in inflammatory bowel disease","volume":"77","author":"Fanizza","year":"2025","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104089_bb0315","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40744-020-00259-8","article-title":"Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for biosimilarity","volume":"8","author":"Huizinga","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.autrev.2026.104089_bb0320","doi-asserted-by":"crossref","first-page":"152395","DOI":"10.1016\/j.semarthrit.2024.152395","article-title":"Response to\u201c do not ignore another risk factor of invasive fungal infections in patients with connective tissue disease","volume":"65","author":"Luo","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2026.104089_bb0325","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.7326\/M21-1757","article-title":"Effect of immunosuppression on the immunogenicity of mRNA Vaccines to SARS-CoV-2: A prospective cohort study","volume":"174","author":"Deepak","year":"2021","journal-title":"Ann Intern Med"},{"issue":"Si2","key":"10.1016\/j.autrev.2026.104089_bb0330","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac206","article-title":"Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis","volume":"61","author":"van der Togt","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.autrev.2026.104089_bb0335","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104089_bb0340","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kead326","article-title":"Hypogammaglobulinemia in rheumatoid arthritis patients on rituximab: prevalence and risk factors","volume":"63","author":"Opdam","year":"2024","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.autrev.2026.104089_bb0345","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004622","article-title":"The effect of rituximab on patient reported outcomes in the preclinical phase of rheumatoid arthritis: 2 year data from the PRAIRI study","volume":"10","author":"Frazzei","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104089_bb0350","doi-asserted-by":"crossref","first-page":"1613878","DOI":"10.3389\/fimmu.2025.1613878","article-title":"CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104089_bb0355","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104089_bb0360","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1002\/art.34426","article-title":"Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis","volume":"64","author":"Brunner","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2026.104089_bb0365","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1007\/s00018-021-03839-1","article-title":"Follicular helper T cells: potential therapeutic targets in rheumatoid arthritis","volume":"78","author":"Lu","year":"2021","journal-title":"Cell Mol Life Sci"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:28:27Z","timestamp":1790494107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1568997226001035"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104089","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The rituximab paradox in rheumatoid arthritis: Re-evaluating B-cell depletion depth and the synovial microenvironment","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104089"}}